Logo Image
NEWS
All NewsFDA BriefsOncology IconsThe Targeted Pulse
CONFERENCES
Conference CoverageConference Listing
MEDIA
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesPodcastsPractice PlaybookShortsVideo SeriesWebinars
PUBLICATIONS
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
More
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
  • NEWS
  • CONFERENCES
  • MEDIA
  • PUBLICATIONS
  • CASE-BASED ROUNDTABLE
  • PARTNERS
  • RESOURCES
  • SUBSCRIBE
  • BRAIN CANCER
  • BREAST CANCER
    • HER2 Breast Cancer
  • COMMUNITY ONCOLOGY PRACTICE
  • GENITOURINARY CANCERS
    • Bladder Cancer
    • Prostate Cancer
    • Renal Cell Carcinoma
  • GENOMIC TESTING
    • Liquid Biopsies
  • GI CANCERS
    • Pancreatic Cancer
    • Colorectal Cancer
    • Gastric Cancer
    • GIST
    • HCC
  • GYNECOLOGIC CANCERS
    • Cervical Cancer
    • Endometrial Cancer
    • Ovarian Cancer
  • HEAD & NECK CANCERS
  • HEMATOLOGY
    • Bone Marrow & Stem Cell Transplant
  • IMMUNOTHERAPY
    • CAR T-Cell Therapy
  • LEUKEMIAS
    • AML
    • Chronic Lymphocytic Leukemia
    • Chronic Myeloid Leukemia
  • LUNG CANCER
    • MET-Targeted Therapy
    • Small Cell Lung Cancer
    • Biomarker-Driven Lung Cancer
    • EGFR+ Lung Cancer
  • LYMPHOMAS
    • DLBCL
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
  • MPNs
  • MULTIPLE MYELOMA
  • NTRK GENE FUSIONS
  • ONCOLOGY POLICY
  • SARCOMA
  • SKIN CANCERS
    • Melanoma
  • THYROID CANCERS
Spotlight -
Community Oncology Practice|
Oncology Policy|
Myeloma|
CLL|
Genomic Testing|
GU Cancers
Advertisement

Jochen H. Lorch, MD, MS

Advertisement

Articles by Jochen H. Lorch, MD, MS

LOXO-101 Trial Regimen Overview

ByJochen H. Lorch, MD, MS
September 21st 2020

Preferred Testing Methods and Treatment Options

ByJochen H. Lorch, MD, MS
September 21st 2020

NTRK Gene Fusion Thyroid Cancer: Incidence and Prognosis

ByJochen H. Lorch, MD, MS
September 21st 2020

A 71-Year-Old Woman With NTRK Gene Fusion Thyroid Cancer

ByJochen H. Lorch, MD, MS
September 21st 2020

A 71-Year-Old Woman with NTRK Gene Fusion Thyroid Cancer

ByJochen H. Lorch, MD, MS
September 21st 2020

A key opinion leader reviews the case of a 71-year-old woman with NTRK gene fusion thyroid cancer and considers novel therapies available for the management of her disease.

Advertisement

Latest Updated Articles

  • Preferred Testing Methods and Treatment Options
    Preferred Testing Methods and Treatment Options

    September 21st 2020

  • LOXO-101 Trial Regimen Overview
    LOXO-101 Trial Regimen Overview

    September 21st 2020

  • A 71-Year-Old Woman With NTRK Gene Fusion Thyroid Cancer
    A 71-Year-Old Woman With NTRK Gene Fusion Thyroid Cancer

    September 21st 2020

  • NTRK Gene Fusion Thyroid Cancer: Incidence and Prognosis
    NTRK Gene Fusion Thyroid Cancer: Incidence and Prognosis

    September 21st 2020



Advertisement
Advertisement

Trending on Targeted Onc

1

FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC

2

Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs

3

Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST

4

FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options

5

Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC

  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • Editorial Board
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us